Business
Masimo to Report Fourth Quarter and Full Year 2025 Financial Results after Market Close on Thursday, February 26
IRVINE, Calif., February 12, 2026--Masimo (NASDAQ: MASI) will release fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after the market closes on Thursday, February 26, 2026. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer.
About this update from Masimo Corporation
Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) IRVINE, Calif., February 12, 2026 --( BUSINESS WIRE )--Masimo (NASDAQ: MASI) will release fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after the market closes on Thursday, February 26, 2026. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call or the webcast, please use the link below. Upon registering, each participant will be provided with details for the call or webcast. Conference Call Registration Link ( Please register to obtain the dial-in number) : Masimo 4Q 2025 Earnings Call A replay will be available shortly after the conclusion of the call and will be archived on the Company’s website. About Masimo Masimo (Nasdaq: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, and patient monitors. Powered by the Masimo Hospital Automation™ and Masimo SafetyNet® platforms, Masimo connectivity, automation, and telehealth and telemonitoring solutions are improving and automating care delivery both in the hospital and beyond. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature . Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20260212813824/en/ Contacts Investor Contact: Eli Kammerman (949) 297-7077 [email protected] Media Contact: Evan Lamb (949) 396-3376 [email protected]
View stock analysis, news, and events for Masimo Corporation